TRAVATAN Z（曲伏前列素眼科溶液）0.004％ 是一种每日一次用药的前列腺素类似物的药物，可减轻眼内压力，增加眼内液体的排泄来起作用。

TRAVATAN Z（曲伏前列素 travoprost）眼用溶液，局部眼用使用0.004％

最初的美国批准：2001年

作用机制

曲伏前列素游离酸，前列腺素类似物是选择性FP前列腺素类受体激动剂，据信其通过增加葡萄膜巩膜外流降低眼内压。 目前确切的作用机制尚不清楚。

适应症和用法

TRAVATANZ®是一种前列腺素类似物，用于降低开角型青光眼或高眼压症患者的眼压升高

剂量和给药

每日一次，晚上使用。

剂型和强度

含有曲伏前列素0.04mg/mL的眼科溶液

禁忌症

没有

警告和注意事项

色素沉着：虹膜，眼周组织（眼睑）和睫毛会发生色素沉着。虹膜色素沉着可能是永久的

睫毛变化：渐变为睫毛，包括增加睫毛长度，厚度和数量。通常可逆

不良反应

最常见的不良反应（30％至50％）是结膜充血

要报告可疑的不良反应，请拨打1-800-757-9195联系Alcon Laboratories Inc.或通过1-800-FDA-1088或www.fda.gov/medwatch联系FDA。

在特定人群中使用

不建议在16岁以下的儿科患者中使用，因为长期慢性使用后与色素沉着增加有关的潜在安全性问题.

如何提供/储存和处理

TRAVATANZ®（曲伏前列素眼用溶液）0.004％是一种无菌，等渗，缓冲，保存的阿尔康椭圆形DROP-TAINER®包装系统中提供的曲伏前列素（0.04 mg/mL）水溶液。

TRAVATANZ®以7.5mL天然聚丙烯分配瓶中4mL和5mL溶液的形式提供2.5mL溶液，天然聚丙烯滴管尖端和绿松石聚丙烯或高密度聚乙烯顶盖。 防篡改证据在包装的封盖和颈部周围设有收缩带。

2.5毫升填充NDC 0065-0260-25

5毫升填入NDC 0065-0260-05

储存：储存在2°C至25°C（36°F-77°F）。

完整说明书附件：https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5549684b-1724-45ca-b67b-590c62b7c149

Important information about TRAVATAN Z® (travoprost ophthalmic solution) 0.004%

INDICATIONS AND USAGE

TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.

TRAVATAN Z® Solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Pigmentation - Travoprost ophthalmic solution has been reported to increase the pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. The long-term effects of increased pigmentation are not known. While treatment with TRAVATAN Z® Solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes - TRAVATAN Z® Solution may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation - TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g. uveitis) because the inflammation may be exacerbated.

Macular Edema - Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z® Solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

Angle-closure, Inflammatory or Neovascular Glaucoma - TRAVATAN Z® Solution has not been eva luated for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

Bacterial Keratitis  - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Use with Contact Lenses - Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reinserted 15 minutes following its administration.

Adverse Reactions

The most common adverse reaction observed in controlled clinical studies with TR